Mandate

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").

The facility is located in Strängnäs and provides specialised expertise and comprehensive services, supporting the development and manufacturing of oral solids and with specialist infrastructure for beta-lactam production. APL, which is now acquiring the facility, is a wholly state-owned company with a social mission to develop and provide a medically appropriate and quality-assured range of extemporaneous medicines and stock preparations. The acquisition is an important step for the Swedish government in strengthening Sweden's preparedness and ensuring access to essential medicines in Sweden, particularly in crisis situations.

Read more on the Government's website here.

Vinge's team consisted of among others Jonas Bergström, Per Kling and Ellenor Eckerborn (M&A), Mathilda Persson and Siri Blomberg (Corporate Commercial), Åsa Hellstadius and Ian Jonson (Life Science).

Related

Vinge has advised Bolero in connection with sale of shares in Ambea AB (publ)

Vinge has advised Bolero Holdings S.à r.l. in connection with the sale of shares in Ambea AB (publ) through an accelerated bookbuilding process carried out on 1 December 2025.
December 02, 2025

Vinge advises on the sale of Segers Fabriker

Vinge has advised the sellers in connection with the sale of Segers Fabriker AB to Norrstigen. Segers is a family-owned company in Borås with operations in Sweden, Estonia, and Ukraine, which has developed and sold workwear for hotels, restaurants, and healthcare since 1943.
December 02, 2025

Vinge has advised Intea Fastigheter in connection with a directed share issue of approximately SEK 500 million

Vinge has advised the property company Intea Fastigheter AB (publ) in connection with a directed share issue of shares of series D through which the company raises proceeds of approximately SEK 500 million before transaction costs. A part of the share issue is subject to subsequent approval at an extraordinary general meeting.
December 01, 2025